“We raised INR 3,500 Cr and there was more demand which we had to politely reject.” wrote cofounder Dhaval Shah on LinkedIn. The goal of the rights issue was to repay a large portion of its debt to Goldman Sachs. PharmEasy parent, API Holdings clocked EBIDTA of INR 60 Cr in the first 6 months of FY24, Shah added.